Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme to gain prenatal genetic testing risk assessment service via Genetrix buy.

This article was originally published in The Gray Sheet

Executive Summary

GENZYME GAINING PRENATAL GENETIC RISK ASSESSMENT PROGRAM VIA GENETRIX acquisition. On Feb. 14, Genzyme announced that it had signed agreement to acquire the privately held Phoenix-based genetic testing company in a stock swap valued at $36.7 mil. In addition to providing genetic testing for cancer monitoring, Genetrix offers a genetic risk assessment service designed to oversee the utilization of prenatal testing for managed care networks in exchange for a capitated fee. Genetrix set up the managed care program a year ago and expects to sign a contract with its first customer, a third-party administrator in Maryland, by the beginning of March.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005527

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel